Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

CD133(+)HIF-1α(−) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer

YUICHI TACHIKAWA, KAZUSHIGE KAWAI, KOSUKE OZAKI, HIROAKI NOZAWA, KAZUHITO SASAKI, KOJI MURONO, SHIGENOBU EMOTO, JUNKO KISHIKAWA, YUICHIRO YOKOYAMA, SHINYA ABE, YUZO NAGAI, HIROYUKI ANZAI, HIROFUMI SONODA and SOICHIRO ISHIHARA
Anticancer Research April 2022, 42 (4) 2033-2043; DOI: https://doi.org/10.21873/anticanres.15684
YUICHI TACHIKAWA
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tachikawa35tsms@gmail.com
KAZUSHIGE KAWAI
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOSUKE OZAKI
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROAKI NOZAWA
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUHITO SASAKI
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOJI MURONO
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIGENOBU EMOTO
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNKO KISHIKAWA
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUICHIRO YOKOYAMA
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINYA ABE
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUZO NAGAI
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYUKI ANZAI
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROFUMI SONODA
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SOICHIRO ISHIHARA
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: CD133 and hypoxia-inducible factor 1α (HIF-1α) have been reported to be affected by chemoradiotherapy (CRT), but the combinatorial assessment of these markers for prognosis after CRT has not been fully investigated. Therefore, we aimed to predict recurrence and prognosis in patients with rectal cancer by assessing changes in the expression of both CD133 and HIF-1α after CRT. Materials and Methods: CD133 and HIF-1α expression was evaluated by immunohistochemistry in surgical specimens from 243 patients with advanced low rectal cancer who received CRT followed by curative resection. Results: The positivity rate of CD133 expression showed increase with increased HIF-1α expression. The combination of these two markers showed that the CD133(+)HIF-1α(−) group exhibited a markedly shorter relapse-free survival (p=0.007), higher liver recurrence (p=0.004), and higher local recurrence (p=0.006). Conclusion: CD133(+)HIF-1α(−) expression after CRT is a promising marker to predict recurrence in rectal cancer.

Key Words:
  • CD133
  • HIF-1α
  • CD133(+)HIF-1α(−)
  • chemoradiotherapy
  • rectal cancer
  • Received January 14, 2022.
  • Revision received February 20, 2022.
  • Accepted February 21, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (4)
Anticancer Research
Vol. 42, Issue 4
April 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
CD133(+)HIF-1α(−) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
15 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
CD133(+)HIF-1α(−) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer
YUICHI TACHIKAWA, KAZUSHIGE KAWAI, KOSUKE OZAKI, HIROAKI NOZAWA, KAZUHITO SASAKI, KOJI MURONO, SHIGENOBU EMOTO, JUNKO KISHIKAWA, YUICHIRO YOKOYAMA, SHINYA ABE, YUZO NAGAI, HIROYUKI ANZAI, HIROFUMI SONODA, SOICHIRO ISHIHARA
Anticancer Research Apr 2022, 42 (4) 2033-2043; DOI: 10.21873/anticanres.15684

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
CD133(+)HIF-1α(−) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer
YUICHI TACHIKAWA, KAZUSHIGE KAWAI, KOSUKE OZAKI, HIROAKI NOZAWA, KAZUHITO SASAKI, KOJI MURONO, SHIGENOBU EMOTO, JUNKO KISHIKAWA, YUICHIRO YOKOYAMA, SHINYA ABE, YUZO NAGAI, HIROYUKI ANZAI, HIROFUMI SONODA, SOICHIRO ISHIHARA
Anticancer Research Apr 2022, 42 (4) 2033-2043; DOI: 10.21873/anticanres.15684
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • CD133
  • HIF-1α
  • CD133(+)HIF-1α(−)
  • chemoradiotherapy
  • Rectal cancer
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire